We Built the Companies Before We Built the Fund
Veracor Capital isn't a fund searching for deals — it's a fund created to scale companies we've already spent 20 years building. The operations came first. The fund came second.
47,000+
Patients Treated
95%
Clinical Success Rate
20+
Years Operating
$4.6M
KureCare 2025 Revenue
6
Portfolio Companies
Yes
Veteran-Owned
Operations First. Fund Second.
2005
Clinical Foundation
Kenton Gray begins developing Signal-Based Medicine protocols in clinical practice, treating chronic disease at the root cause level.
2010
KureCare Launch
Wound care division established under Max Health LA, achieving 95% healing rates that exceed Medicare benchmarks. Revenue begins scaling.
2015
10,000 Patients Treated
Milestone reached across clinical programs, validating the Signal-Based Medicine methodology at scale across multiple conditions.
2018
EliteMD Network Established
Medical director network created, generating recurring SaaS-like revenue across healthcare organizations. National coverage begins.
2020
Pure Pak Acquisition
FDA-registered 150,000 sq ft contract manufacturer acquired, completing vertical integration of the supplement supply chain.
2022
Veracor Capital Formation
Fund management entity formed to deploy institutional capital into the Kure Healthcare Ecosystem — backing companies the team already built.
2023
Kure Health Ecosystem Fund I
$50M target raise launched for accredited investors. Signal-Based Medicine IP formalized as core competitive moat.
2024
RIIZE Year One — $3.6M
RIIZE STRIPS launches as a prescription-based product, generating $3.6M in first-year revenue. Strategic decision made to pivot to DTC-only model for 2025+.
2025
Build Year — Ecosystem Retooling
KureCare hits $4.6M revenue. RIIZE undergoes full DTC retooling. Women's Fund structured. KureOS AI platform enters development. Infrastructure year for 2026 launch.
2026
Launch Year
Multi-fund strategy goes live. RIIZE DTC launches nationwide. Reg CF filing opens retail investor access. KureOS AI enters clinical pilots.
A New Fund Backed by Two Decades of Proof
We Built It Before We Funded It
Most funds raise capital then search for deals. We spent 20 years building KureCare, EliteMD, Pure Pak, and the clinical infrastructure — then formed a fund to scale what already works. The risk profile is fundamentally different.
Revenue Today, Not Promises
KureCare generated $4.6M in 2025. RIIZE did $3.6M in its first year. These aren't pre-revenue bets — they're operating companies being retooled for exponential growth in 2026. Pure Pak manufactures product at scale today.
Founder-Operator Alignment
Kenton Gray built these companies before raising outside capital. 2025 was an intentional build year — retooling RIIZE from prescription to DTC, developing KureOS, and structuring the multi-fund strategy. His track record is the fund's track record.